KROS supply chain intelligence for Keros Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| HANSOH-SHANGHAI-HEALTHTECH-CO-LTD | HANSOH-SHANGHAI-HEALTHTECH-CO-LTD | 90% | We are dependent on our existing third-party collaborations with Takeda Pharmaceuticals U.S.A., Inc., or Takeda, and Hansoh (Shanghai) Healthtech Co., Ltd., or Hansoh, to commercial elritercept |
| TAKEDA-PHARMACEUTICALS-U-S-A-INC | TAKEDA-PHARMACEUTICALS-U-S-A-INC | 90% | On December 3, 2024, the Company entered into a license agreement with Takeda Pharmaceuticals U.S.A., Inc. ("Takeda"), which became effective on January 16, 2025 |
| BMY | Bristol-Myers Squibb Company | 72% | nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems wi… |
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from KROS graph: nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fa… |
| BMYMP | Bristol-Myers Squibb Co | 72% | nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems wi… |
| BMYMP | Bristol-Myers Squibb Co | 72% | Reciprocal relationship from BMYMP graph: Reciprocal relationship from KROS graph: Reciprocal relationship from BMYMP graph: Reciprocal relationship from KROS graph: nued regulatory review, which may… |
| EWTX | Edgewise Therapeutics, Inc. | 72% | Reciprocal relationship from EWTX graph: Reciprocal relationship from KROS graph: nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we f… |
| EWTX | Edgewise Therapeutics, Inc. | 72% | nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems wi… |
| IBIO | iBio, Inc. | 72% | Reciprocal relationship from IBIO graph: Reciprocal relationship from KROS graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from KROS graph: Reciprocal relationship from IBIO g… |
| MSLE | MSLE | 72% | nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems wi… |
| MSLE | MSLE | 72% | Reciprocal relationship from MSLE graph: Reciprocal relationship from KROS graph: nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we f… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems wi… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | Reciprocal relationship from REGN graph: Reciprocal relationship from KROS graph: Reciprocal relationship from REGN graph: Reciprocal relationship from KROS graph: nued regulatory review, which may r… |
| RNAM | RNAM | 72% | nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems wi… |
| RNAM | RNAM | 72% | Reciprocal relationship from RNAM graph: Reciprocal relationship from KROS graph: Reciprocal relationship from RNAM graph: Reciprocal relationship from KROS graph: nued regulatory review, which may r… |
| SRPT | Sarepta Therapeutics, Inc. | 72% | Reciprocal relationship from SRPT graph: Reciprocal relationship from KROS graph: nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we f… |
| SRPT | Sarepta Therapeutics, Inc. | 72% | nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems wi… |
| SRRK | Scholar Rock Holding Corporation | 72% | nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems wi… |
| SRRK | Scholar Rock Holding Corporation | 72% | Reciprocal relationship from SRRK graph: Reciprocal relationship from KROS graph: Reciprocal relationship from SRRK graph: Reciprocal relationship from KROS graph: nued regulatory review, which may r… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| HANSOH-SHANGHAI-HEALTHTECH-CO-LTD | HANSOH-SHANGHAI-HEALTHTECH-CO-LTD | 92% | In connection with the Hansoh Agreement, Hansoh will purchase clinical trial supply of elritercept from the Company |
| MASSACHUSETTS-GENERAL-HOSPITAL | MASSACHUSETTS-GENERAL-HOSPITAL | 90% | the Company has entered into an agreement with the Massachusetts General Hospital for the design of a Phase 2 clinical trial evaluating rinvatercept in patients with amyotrophic lateral sclerosis |
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from KROS graph: Reciprocal relationship from BMY graph: Reciprocal relationship from KROS graph: nued regulatory review, which may res… |
| BMY | Bristol-Myers Squibb Company | 72% | nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems wi… |
| BMYMP | Bristol-Myers Squibb Co | 72% | Reciprocal relationship from BMYMP graph: Reciprocal relationship from KROS graph: nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we … |
| BMYMP | Bristol-Myers Squibb Co | 72% | nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems wi… |
| EWTX | Edgewise Therapeutics, Inc. | 72% | nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems wi… |
| EWTX | Edgewise Therapeutics, Inc. | 72% | Reciprocal relationship from EWTX graph: Reciprocal relationship from KROS graph: nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we f… |
| GOSS | Gossamer Bio, Inc. | 72% | Reciprocal relationship from GOSS graph: Reciprocal relationship from KROS graph: nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we f… |
| GOSS | Gossamer Bio, Inc. | 72% | nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems wi… |
| IBIO | iBio, Inc. | 72% | Reciprocal relationship from IBIO graph: Reciprocal relationship from KROS graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from KROS graph: Reciprocal relationship from IBIO g… |
| MSLE | MSLE | 72% | Reciprocal relationship from MSLE graph: Reciprocal relationship from KROS graph: Reciprocal relationship from MSLE graph: Reciprocal relationship from KROS graph: Reciprocal relationship from MSLE g… |
| MSLE | MSLE | 72% | nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems wi… |
| PTCT | PTC Therapeutics, Inc. | 72% | Reciprocal relationship from PTCT graph: Reciprocal relationship from KROS graph: Reciprocal relationship from PTCT graph: Reciprocal relationship from KROS graph: Reciprocal relationship from PTCT g… |
| PTCT | PTC Therapeutics, Inc. | 72% | nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems wi… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | Reciprocal relationship from REGN graph: Reciprocal relationship from KROS graph: nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we f… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems wi… |
| RNAM | RNAM | 72% | nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems wi… |
| RNAM | RNAM | 72% | Reciprocal relationship from RNAM graph: Reciprocal relationship from KROS graph: nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we f… |
| SLDB | Solid Biosciences Inc. | 72% | nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems wi… |
| SLDB | Solid Biosciences Inc. | 72% | Reciprocal relationship from SLDB graph: Reciprocal relationship from KROS graph: Reciprocal relationship from SLDB graph: Reciprocal relationship from KROS graph: Reciprocal relationship from SLDB g… |
| SRPT | Sarepta Therapeutics, Inc. | 72% | Reciprocal relationship from SRPT graph: Reciprocal relationship from KROS graph: nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we f… |
| SRPT | Sarepta Therapeutics, Inc. | 72% | nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems wi… |
| SRRK | Scholar Rock Holding Corporation | 72% | Reciprocal relationship from SRRK graph: Reciprocal relationship from KROS graph: nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we f… |
| SRRK | Scholar Rock Holding Corporation | 72% | nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems wi… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| KROS-DEBT-10570 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2020-12-31. |
| KROS-DEBT | Debt stack $16.3M | 90% | Market cache reports total debt of $16.3M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| KROS-OWNER-BLACKROCK-INC | BlackRock, Inc. | 90% | 13F overlay lists BlackRock, Inc. as top holder; 152 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| CCEP | Coca-Cola Europacific Partners PLC | 100.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| CPRX | Catalyst Pharmaceuticals, Inc. | 100.00 | 2 | |
| WHWK | Whitehawk Therapeutics, Inc. | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| BLRX | BioLineRx Ltd. | 100.00 | 2 | |
| CLYM | Climb Bio, Inc. | 100.00 | 2 | |
| DAWN | Day One Biopharmaceuticals Inc | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| AXSM | Axsome Therapeutics, Inc. | 100.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 2 | |
| EMMA | Emmaus Life Sciences, Inc. | 100.00 | 2 | |
| BNBX | BNB Plus Corp. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 100.00 | 2 | |
| BEAM | Beam Therapeutics Inc. | 100.00 | 2 | |
| CBIO | Crescent Biopharma, Inc. | 100.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 2 | |
| PSNL | Personalis, Inc. | 100.00 | 2 |